|
1
|
Giordano A and Cito L: Advances in gastric
cancer prevention. World J Clin Oncol. 3:128–136. 2012.PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mbulaiteye SM, Hisada M and El-Omar EM:
Helicobacter pylori associated global gastric cancer burden. Front
Biosci (Landmark Ed). 14:1490–1504. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee YY and Derakhshan MH: Environmental
and lifestyle risk factors of gastric cancer. Arch Iran Med.
16:358–365. 2013.PubMed/NCBI
|
|
5
|
Schuhmacher C, Reim D and Novotny A:
Neoadjuvant treatment for gastric cancer. J Gastric Cancer.
13:73–78. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lordick F, Lorenzen S, Yamada Y and Ilson
D: Optimal chemotherapy for advanced gastric cancer: Is there a
global consensus? Gastric Cancer. 17:213–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu YR, Jiang YZ, Zuo WJ, Yu KD and Shao
ZM: PIK3CA mutations define favorable prognostic biomarkers in
operable breast cancer: A systematic review and meta-analysis. Onco
Targets Ther. 7:543–552. 2014.PubMed/NCBI
|
|
8
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartels CL and Tsongalis GJ: MicroRNAs:
Novel biomarkers for human cancer. Clin Chem. 55:623–631. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ke TW, Wei PL, Yeh KT, Chen WT and Cheng
YW: MiR-92a promotes cell metastasis of colorectal cancer through
PTEN- mediated PI3K/AKT pathway. Ann Surg Oncol. 22:2649–2655.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
|
|
12
|
Slabý O, Krekác D, Hrstka R, Svoboda M and
Vyzula R: Involvement of microRNAs in cancer biology and
possibilities of their application to diagnostic and predictive
oncology. Cas Lek Cesk. 147:25–31. 2008.(In Czech). PubMed/NCBI
|
|
13
|
Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J,
Jiang B, Shu Y and Liu P: miR-200bc/429 cluster modulates multidrug
resistance of human cancer cell lines by targeting BCL2 and XIAP.
Cancer Chemother Pharmacol. 69:723–731. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sossey-Alaoui K, Bialkowska K and Plow EF:
The miR200 family of microRNAs regulates WAVE3-dependent cancer
cell invasion. J Biol Chem. 284:33019–33029. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Smith CM, Watson DI, Leong MP, Mayne GC,
Michael MZ, Wijnhoven BP and Hussey DJ: miR-200 family expression
is downregulated upon neoplastic progression of Barrett's
esophagus. World J Gastroenterol. 17:1036–1044. 2011.PubMed/NCBI
|
|
16
|
Zhang Y, Li M, Wang H, Fisher WE, Lin PH,
Yao Q and Chen C: Profiling of 95 microRNAs in pancreatic cancer
cell lines and surgical specimens by real-time PCR analysis. World
J Surg. 33:698–709. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Y, Zuo J, Liu Y, Gao H and Liu W:
Inhibitory effects of miRNA-200c on chemotherapy-resistance and
cell proliferation of gastric cancer SGC7901/DDP cells. Chin J
Cancer. 29:1006–1011. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hill L, Browne G and Tulchinsky E:
ZEB/miR-200 feedback loop: At the crossroads of signal transduction
in cancer. Int J Cancer. 132:745–754. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Haslehurst AM, Koti M, Dharsee M, Nuin P,
Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, et al: EMT
transcription factors snail and slug directly contribute to
cisplatin resistance in ovarian cancer. BMC Cancer. 12:912012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adam L, Zhong M, Choi W, Qi W, Nicoloso M,
Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, et al:
miR-200 expression regulates epithelial-to-mesenchymal transition
in bladder cancer cells and reverses resistance to epidermal growth
factor receptor therapy. Clin Cancer Res. 15:5060–5072. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Washington K: 7th edition of the AJCC
cancer staging manual: stomach. Ann Surg Oncol. 17:3077–3079. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamaue H, Tanimura H, Noguchi K, Hotta T,
Tani M, Tsunoda T, Iwahashi M, Tamai M and Iwakura S:
Chemosensitivity testing of fresh human gastric cancer with highly
purified tumour cells using the MTT assay. Br J Cancer. 66:794–799.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kelley JR and Duggan JM: Gastric cancer
epidemiology and risk factors. J Clin Epidemiol. 56:1–9. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee JH, Kim KM, Cheong JH and Noh SH:
Current management and future strategies of gastric cancer. Yonsei
Med J. 53:248–257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hudler P: Genetic aspects of gastric
cancer instability. ScientificWorldJournal. 2012:7619092012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yan LH, Wei WY, Cao WL, Zhang XS, Xie YB
and Xiao Q: Overexpression of E2F1 in human gastric carcinoma is
involved in anti-cancer drug resistance. BMC Cancer. 14:9042014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kang JH, Lee SI, Lim DH, Park KW, Oh SY,
Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, et al: Salvage
chemotherapy for pretreated gastric cancer: A randomized phase III
trial comparing chemotherapy plus best supportive care with best
supportive care alone. J Clin Oncol. 30:1513–1518. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun F, Lu X, Li H, Peng Z, Wu K, Wang G
and Tong Q: Special AT-rich sequence binding protein 1 regulates
the multidrug resistance and invasion of human gastric cancer
cells. Oncol Lett. 4:156–162. 2012.PubMed/NCBI
|
|
29
|
Zhang H, Sun LL, Meng YL, Song GY, Hu JJ,
Lu P and Ji B: Survival trends in gastric cancer patients of
Northeast China. World J Gastroenterol. 17:3257–3262.
2011.PubMed/NCBI
|
|
30
|
Maconi G, Manes G and Porro GB: Role of
symptoms in diagnosis and outcome of gastric cancer. World J
Gastroenterol. 14:1149–1155. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Montagnani F, Turrisi G, Marinozzi C,
Aliberti C and Fiorentini G: Effectiveness and safety of
oxaliplatin compared to cisplatin for advanced, unresectable
gastric cancer: a systematic review and meta-analysis. Gastric
Cancer. 14:50–55. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang J, Yang M, Li Y and Han B: The role
of microRNAs in the chemoresistance of breast cancer. Drug Dev Res.
76:368–374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang L, Guo F, Wang Y, Lv Y, Huo B, Wang
L and Liu W: MicroRNA-200c regulates the sensitivity of
chemotherapy of gastric cancer SGC7901/DDP cells by directly
targeting RhoE. Pathol Oncol Res. 20:93–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Issabekova A, Berillo O, Regnier M and
Anatoly I: Interactions of intergenic microRNAs with mRNAs of genes
involved in carcinogenesis. Bioinformation. 8:513–518. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hong L, Han Y, Lu Q, Zhang H, Zhao Q, Wu K
and Fan D: Drug resistance-related microRNAs in esophageal cancer.
Expert Opin Biol Ther. 12:1487–1494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sato F, Tsuchiya S, Meltzer SJ and Shimizu
K: MicroRNAs and epigenetics. FEBS J. 278:1598–1609. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM
and Zhang GZ: Biological functions of microRNAs: A review. J
Physiol Biochem. 67:129–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Korpal M and Kang Y: The emerging role of
miR-200 family of microRNAs in epithelial-mesenchymal transition
and cancer metastasis. RNA Biol. 5:115–119. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hurteau GJ, Carlson JA, Spivack SD and
Brock GJ: Overexpression of the microRNA hsa-miR-200c leads to
reduced expression of transcription factor 8 and increased
expression of E-cadherin. Cancer Res. 67:7972–7976. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Knezevic J, Pfefferle AD, Petrovic I,
Greene SB, Perou CM and Rosen JM: Expression of miR-200c in
claudin-low breast cancer alters stem cell functionality, enhances
chemosensitivity and reduces metastatic potential. Oncogene.
34:5997–6006. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bai WD, Ye XM, Zhang MY, Zhu HY, Xi WJ,
Huang X, Zhao J, Gu B, Zheng GX, Yang AG, et al: MiR-200c
suppresses TGF-β signaling and counteracts trastuzumab resistance
and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J
Cancer. 135:1356–1368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu N, Zeng J, Zhang X, Yang Q, Liao D,
Chen G and Wang Y: Involvement of miR-200a in chemosensitivity
regulation of ovarian cancer. Zhonghua Yi Xue Za Zhi. 94:2148–2151.
2014.(In Chinese). PubMed/NCBI
|
|
44
|
Zheng L, Zhang Y, Liu Y, Zhou M, Lu Y,
Yuan L, Zhang C, Hong M, Wang S and Li X: MiR-106b induces cell
radioresistance via the PTEN/PI3K/AKT pathways and p21 in
colorectal cancer. J Transl Med. 13:2522015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ritchie W, Rasko JE and Flamant S:
MicroRNA target prediction and validation. Adv Exp Med Biol.
774:39–53. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Witkos TM, Koscianska E and Krzyzosiak WJ:
Practical aspects of microRNA target prediction. Curr Mol Med.
11:93–109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Panda H, Pelakh L, Chuang TD, Luo X,
Bukulmez O and Chegini N: Endometrial miR-200c is altered during
transformation into cancerous states and targets the expression of
ZEBsVEGFAFLT1IKKβKLF9, and FBLN5. Reprod Sci. 19:786–796. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lee JY, Park MK, Park JH, Lee HJ, Shin DH,
Kang Y, Lee CH and Kong G: Loss of the polycomb protein Mel-18
enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2
expression through the downregulation of miR-205 in breast cancer.
Oncogene. 33:1325–1335. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nam EH, Lee Y, Park YK, Lee JW and Kim S:
ZEB2 upregulates integrin α5 expression through cooperation with
Sp1 to induce invasion during epithelial-mesenchymal transition of
human cancer cells. Carcinogenesis. 33:563–571. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kakihana M, Ohira T, Chan D, Webster RB,
Kato H, Drabkin HA and Gemmill RM: Induction of E-cadherin in lung
cancer and interaction with growth suppression by histone
deacetylase inhibition. J Thorac Oncol. 4:1455–1465. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fang S, Zeng X, Zhu W, Tang R, Chao Y and
Guo L: Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by
miR-200b contributes to multi-drug resistance of small cell lung
cancer. Exp Mol Pathol. 96:438–444. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Schickel R, Park SM, Murmann AE and Peter
ME: miR-200c regulates induction of apoptosis through CD95 by
targeting FAP-1. Mol Cell. 38:908–915. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tryndyak VP, Beland FA and Pogribny IP:
E-cadherin transcriptional down-regulation by epigenetic and
microRNA-200 family alterations is related to mesenchymal and
drug-resistant phenotypes in human breast cancer cells. Int J
Cancer. 126:2575–2583. 2010.PubMed/NCBI
|
